Sequoia Capital's newly appointed co-stewards, Pat Grady and Alfred Lin, are pursuing a radically different strategy than typical venture investors: they're holding their chips in three competing frontier AI labs rather than taking profits when those companies go public. Since taking the helm in late 2025, the pair have raised $10 billion across multiple funds and invested $2.5 billion in Anthropic, while maintaining significant stakes in OpenAI and xAI.

Why Is Sequoia Backing Three AI Competitors at Once?

Sequoia's approach breaks with venture capital tradition. Historically, firms back one leading company per category to avoid conflicts and maximize returns when that single winner emerges. But Grady and Lin are betting differently on the AI race. The firm holds stakes in three frontier model companies: OpenAI, in which Sequoia first invested in 2021; Anthropic, a newer competitor; and xAI, which became part of Sequoia's portfolio when SpaceX acquired it.

This diversified bet reflects confidence that the AI market is large enough to support multiple winners. Beyond frontier models, Sequoia is also doubling down on startups using AI to outcompete legacy software incumbents across verticals including law, health, and cybersecurity. The firm's thesis is straightforward: there is significant opportunity for AI-native startups to displace entrenched software companies that haven't adapted to artificial intelligence.

What Are Sequoia's Long-Term Targets for These AI Companies?

Rather than viewing upcoming initial public offerings as exit opportunities, Grady has articulated an ambitious vision for each of the three frontier AI labs. According to Grady, Sequoia's long-term target for each company, SpaceX, OpenAI, and Anthropic, is approximately $10 trillion in market capitalization. For context, that would place each company among the most valuable enterprises ever created, far exceeding current valuations.

"Our long-term target on each of SpaceX, OpenAI, and Anthropic is about $10 trillion of market cap. Yes, an IPO would be a nice liquidity event. We probably will not take much advantage of that liquidity," said Pat Grady.

Pat Grady, Co-steward at Sequoia Capital

This statement signals that Sequoia views these companies as multi-decade wealth creators rather than near-term exits. Even as each company eyes or executes an initial public offering in 2026, Sequoia plans to hold its positions, betting that the long-term upside far exceeds the liquidity available from selling shares at IPO prices.

How to Understand Sequoia's AI Investment Strategy

• Frontier Model Exposure: Sequoia maintains stakes in three competing large language model companies, giving the firm exposure to multiple potential winners in the race to build advanced AI systems.
• Vertical AI Plays: Beyond frontier models, Sequoia is investing in startups applying AI to specific industries like law, health, and cybersecurity, betting these companies can outcompete legacy software providers.
• Long-Term Hold Strategy: Rather than taking profits at IPO, Sequoia plans to hold positions in OpenAI, Anthropic, and xAI, targeting valuations around $10 trillion per company over the long term.

The leadership transition itself marks a historic moment for Sequoia. Grady and Lin's appointment as co-stewards represents only the fourth leadership change in the firm's 54-year history, underscoring the significance of the shift. Both executives have moved quickly to reshape Sequoia's portfolio and strategy around AI, raising substantial new capital and making bold bets on companies that may not generate returns for years or decades.

This approach reflects a broader confidence in the transformative potential of frontier AI. Rather than treating AI investments as a short-term opportunity to capitalize on hype, Sequoia's leadership is positioning the firm for a future in which artificial intelligence becomes the foundational technology underlying most valuable enterprises. By holding stakes in multiple frontier labs and backing AI-native startups across industries, Sequoia is betting that the AI revolution will create trillions of dollars in new value, and that patient capital will be rewarded far more generously than quick exits.